Related Experiment Video
Updated: Apr 19, 2026

Use of a Hanging-weight System for Isolated Renal Artery Occlusion
Published on: July 19, 2011
Evidence-Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease
Sourabh Sharma1, Sanjay Kalra2,3, Manisha Sahay4
1Department of Nephrology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
None:
In patients with chronic kidney disease (CKD), the burden of atherosclerotic cardiovascular disease (ASCVD) remains distinctively high. Management of dyslipidaemia in individuals with CKD is essential yet often deficient due to polypharmacy, poor adherence, and statin intolerance. Inclisiran, a small interfering RNA (siRNA) that targets hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis, offers an innovative, long-acting approach to lower LDL-cholesterol. This manuscript presents evidence-based recommendations based on available clinical trial evidence and collective specialist opinion. We propose a practical stratification tool (Inclisiran Suitability Stratification Tool for CKD) and treatment algorithm, comparing Inclisiran with other lipid-lowering agents to support individualized clinical decision-making.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

